Lerner B. Screening for cancer: a downside. New York Times.March 5, 2002:D6.
Kolata G. Lung cancer test is much in demand, but benefit is murky. New York Times.June 21, 2001:A1-A14.
Brice J. Low-dose CT: the promise and the paradox of lung cancer screening. Diagn Imaging (San Franc).2000;22:44-53.
Lee TH, Brennan TA. Direct-to-consumer marketing of high-technology screening tests. N Engl J Med.2002;346:529-531.
Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer.1995;75(suppl 1):191-202.
Fontana RS, Sanderson DR, Woolner LB, Taylor WF, Miller WE, Muhm JR. Lung cancer screening: the Mayo program. J Occup Med.1986;28:746-750.
Tockman MS. Survival and mortality from lung cancer in a screened population: the
Johns Hopkins study. Chest.1986;89(suppl 4):324S-326S.
Melamed MR, Flehinger BJ, Zaman MB. Impact of early detection on the clinical course of lung cancer. Surg Clin North Am.1987;67:909-924.
Kubik A, Parkin DM, Khlat M, Erban J, Polak J, Adamec M. Lack of benefit from semi-annual screening for cancer of the lung:
follow-up report of a randomized controlled trial on a population of high-risk
males in Czechoslovakia. Int J Cancer.1990;45:26-33.
Fontana RS, Sanderson DR, Woolner LB.
et al. Screening for lung cancer: a critique of the Mayo Lung Project. Cancer.1991;67(suppl 4):1155-1164.
Hulka BS. Screening for cancer: lessons learned. J Occup Med.1986;28:687-691.
Henschke CI, McCauley DI, Yankelevitz DF.
et al. Early Lung Cancer Action Project: overall design and findings from
baseline screening. Lancet.1999;354:99-105.
Henschke CI, Naidich DP, Yankelevitz DF.
et al. Early lung cancer action project: initial findings on repeat screenings. Cancer.2001;92:153-159.
Sone S, Li F, Yang ZG.
et al. Results of three-year mass screening programme for lung cancer using
mobile low-dose spiral computed tomography scanner. Br J Cancer.2001;84:25-32.
Swensen SJ, Jett JR, Sloan JA.
et al. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med.2002;165:508-513.
Sone S, Takashima S, Li F.
et al. Mass screening for lung cancer with mobile spiral computed tomography
Sobue T, Moriyama N, Kaneko M.
et al. Screening for lung cancer with low-dose helical computed tomography:
anti-lung cancer association project. J Clin Oncol.2002;20:911-920.
Patz Jr EF, Goodman PC, Bepler G. Screening for lung cancer. N Engl J Med.2000;343:1627-1633.
Kaneko M, Eguchi K, Ohmatsu H.
et al. Peripheral lung cancer: screening and detection with low-dose spiral
CT versus radiography. Radiology.1996;201:798-802.
Henschke CI, Yankelevitz DF. CT screening for lung cancer. Radiol Clin North Am.2000;38:487-495.
Patz Jr EF, Rossi S, Harpole Jr DH, Herndon JE, Goodman PC. Correlation of tumor size and survival in patients with stage IA non-small
cell lung cancer. Chest.2000;117:1568-1571.
National Cancer Institute and the American Cancer Society. Early Lung Cancer Screening Workshop. March 7-8, 2001; Rockville, Md.
National Institutes of Health, National Cancer Institute. Fifty thousand current and former smokers needed for National Lung
Screening Trial [press release]. September 18, 2002. Available at: http://www.nih.gov/news/pr/sep2002/nci-19a.htm. Accessibility verified December 18, 2002.
Sprial CT screens raise scientific, economic issues. Oncol News Int.2000;9:1-30.
Kolata G. Questions grow over usefulness of some routine cancer tests. New York Times.December 30, 2001:A1-A16.
Grannis Jr F. Lung cancer screening: who will pick up the tab? Chest.2002;121:1388-1390.
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER)
Program Public-Use Data (1973-1998) [database on CD-ROM]. Bethesda, Md: National Cancer Institute; 2001.
DevCan: Probability of Developing or Dying of Cancer [computer
program]. Bethesda, Md: National Cancer Institute; 2001.
DeCamp Jr MM, Jaklitsch MT, Mentzer SJ, Harpole Jr DH, Sugarbaker DJ. The safety and versatility of video-thoracoscopy: a prospective analysis
of 895 consecutive cases. J Am Coll Surg.1995;181:113-120.
Jaklitsch MT, DeCamp Jr MM, Liptay MJ.
et al. Video-assisted thoracic surgery in the elderly: a review of 307 cases. Chest.1996;110:751-758.
Celik M, Halezeroglu S, Senol C.
et al. Video-assisted thoracoscopic surgery: experience with 341 cases. Eur J Cardiothorac Surg.1998;14:113-116.
Shah SS, Tsang V, Goldstraw P. Open lung biopsy: a safe, reliable, and accurate method for diagnosis
in diffuse lung disease. Respiration.1992;59:243-246.
Sagel SS, Ferguson TB, Forrest JV, Roper CL, Weldon CS, Clark RE. Percutaneous transthoracic aspiration needle biopsy. Ann Thorac Surg.1978;26:399-405.
Bach PB, Cramer LD, Schrag D, Downey RJ, Gelfand SE, Begg CB. The influence of hospital volume on survival after resection for lung
cancer. N Engl J Med.2001;345:181-188.
Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics.2001;19:855-863.
Earle CC, Chapman RH, Baker CS.
et al. Systematic overview of cost-utility assessments in oncology. J Clin Oncol.2000;18:3302-3317.
American Medical Association. 1998 National Physician Fee Schedule Relative Value
File. Chicago, Ill: American Medical Association; 1998.
Thomson Healthcare. Red Book: Drug Topics 2001. Montvale, NJ: Medical Economics Co Inc; 2001.
Fireman BH, Quesenberry CP, Somkin CP.
et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev.1997;18:51-76.
National Alliance for Caregiving (NAC), American Association of Retired
Persons (AARP). Caregiving in the United States: Findings From a
National Survey. Bethesda, Md and Washington, DC: NAC/AARP; 2001.
Hillner BE, Smith TJ. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine)
for non-small cell lung cancer. Semin Oncol.1996;23(suppl 2 pt 5):25-30.
Gurley MB, Richli WR, Waugh KA. Outpatient management of pneumothorax after fine-needle aspiration:
economic advantages for the hospital and patient. Radiology.1998;209:717-722.
Data Pro Pro [computer program]. Version 6.0. Boston, Mass: TreeAge Inc; 2002.
Burns DM. Primary prevention, smoking, and smoking cessation: implications for
future trends in lung cancer prevention. Cancer.2000;89(suppl 11):2506-2509.
Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination
of national statistics with two case-control studies. BMJ.2000;321:323-329.
Eddy DM. Screening for lung cancer. Ann Intern Med.1990;112:73-74.
Melamed MR, Flehinger BJ, Zaman MB, Heelan RT, Perchick WA, Martini N. Screening for early lung cancer: results of the Memorial Sloan-Kettering
study in New York. Chest.1984;86:44-53.
Walter SD, Kubik A, Parkin DM, Reissigova J, Adamec M, Khlat M. The natural history of lung cancer estimated from the results of a
randomized trial of screening. Cancer Causes Control.1992;3:115-123.
Dolan P. Modeling valuations for EuroQoL health states. Med Care.1997;35:1095-1108.
Palmisano WA, Divine KK, Saccomanno G.
et al. Predicting lung cancer by detecting aberrant promoter methylation in
sputum. Cancer Res.2000;60:5954-5958.
Harris RP, Helfand M, Woolf SH.
et al. Current methods of the US Preventive Services Task Force: a review
of the process. Am J Prev Med.2001;20(suppl 3):21-35.
Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals
in the United States: a national cancer data base report. Cancer.1999;86:1867-1876.